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cular arrhythmias (VA), heart failure (Killip class>1) and 30-day mortality
were collected.
 
Results:
 
 Among the 1541 patients included in the study, 693 patients
presented PIA. Baseline clinical characteristics were similar for the 2
groups. There was no significant difference for the GRACE risk score
(p=0.942). However, PIA was associated with a lower creatine kinase
peak, as a reflect of infarct size (231(109-520) vs. 322(148-844) IU/L,
p<0.001) and a lower rate of patients with a troponin peak >100 ULN
(31% vs. 39%, p<0.001) when compared with the group without PIA.
Patients with PIA were admitted with markedly less pre-hospital RCA
(0.6% vs. 3.4%, p<0.001) and developed fewer VA (1.6% vs. 4.0%,
p=0.008) and heart failure (18.2% vs. 22.6%, p=0.037) during the hospital
stay. There was a trend toward a decrease in 30-day death in patients with
PIA (4.3% vs 6.1%, p=0.146).
 
Conclusion:
 
 From this large contemporary observational study, PIA is
observed in almost 50% of patients admitted for a first NSTEMI. In such
patients, PIA is associated with less pre-hospital RCA, and decreased in-hos-
pital VA and heart failure. These findings suggest that identifying lack of PIA
in patients admitted for a NSTEMI could help for early risk stratification, in
particular for ventricular arrhythmias.
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Context:
 
 Assessment of bleeding risk is often crucial for making decisions
regarding chronic use of antithrombotics.
 
Objective:
 
 To develop a risk score to quantify bleeding risk in outpa-
tients. Design, Setting, and Participants We studied patients enrolled in the
Reduction of Atherothrombosis for Continued Health (REACH) Registry,
a cohort of 68 236 patients with or at risk of atherothrombosis. The out-
come of interest was serious bleeding (non-fatal hemorrhagic stroke or
bleeding requiring hospitalization and transfusion) over 2 years. Risk fac-
tors for bleeding were assessed using modified regression analysis. Mul-
tiple potential scoring systems based on the least complex models were
constructed. Competing scores were compared on their discriminative abi-
lity via logistic regression. The score was validated externally using the
CHARISMA population.
 
Results:
 
 From a final cohort of 56 616 patients, 804 (1.42%) experienced
serious bleeding between baseline and 2 years. A nine-item bleeding risk
score, ranging from 0 to 23 points, was constructed including age, peripheral
arterial disease, congestive heart failure, diabetes, hypertension, smoking, anti-
platelets, oral anticoagulants, and hypercholesterolemia. Observed incidence
of bleeding at 2 years was: 0.46% in patients with a score 
 
≤
 
6; 0.95% for scores
7-8; 1.25% for scores 9-10; and 2.76% for scores 
 
≥
 
11. The score’s discrimi-
native performance was consistent in CHARISMA and REACH (c-statistics
0.63 and 0.68, respectively); calibration in the CHARISMA population was
very good (modified Hosmer-Lemeshow 
 
χ
 
2
 
=4.74; 
 
P
 
=.69).
 
Conclusions:
 
 Bleeding risk increases dramatically with a score >10. This
score can assist clinicians in predicting the risk of serious bleeding and making
decisions on antithrombotic therapy in outpatients with atherothrombosis.
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Aim:
 
 The CHADS
 
2
 
 score is a reliable, easy-to-use, and popular bedside
score to assess the risk of stroke in patients with atrial fibrillation (AF). The
items of the score are all key determinants of prognosis in vascular patients.
We compare CHADS
 
2
 
 to established scores (the Framingham score and the
European SCORE) for their ability to predict adverse cardiovascular outcome
in atherothrombotic patients without AF.
 
Methods: 
 
Individual risk scores were calculated in 18,888 stable athe-
rothrombotic patients without AF included in the European REACH registry in
18 European countries between 2003 and 2004. Each scheme was divided into
low, intermediate and high predicted risk categories and applied to the cohort.
MACCE (CV Death, MI or Stroke) were recorded at 2 years follow-up.
 
Results:
 
 Two hundred six deaths and 987 MACCE occurred during 37776
patients-years follow up. According to CHADS
 
2
 
 score, 38.2% (7234 patients with
CHADS
 
2
 
=0-1) had low, 48.2% (9101 patients with CHADS
 
2
 
=2-3) had interme-
diate and 13.5% had high predicted CV risk (2553 patients with CHADS
 
2
 
=4-6)
(figure A). The proportion of individual assigned to individual risk categories
varied widely across schemes (low risk ranged from 26.6 % to 88.6%, high risk
from 1.5% to 25.0%). Although the risk scores had only poor discriminating abi-
lity, CHADS
 
2
 
 had the higher c-statistics of 0.613 (figure B). In multivariable
logistic regression, the CHADS
 
2
 
 score (high vs low risk) remains an independent
predictor of MACCE even after adjustement to Framingham score (OR 2.78 [95%
CI 2.3 to 3.3] ) or european SCORE (OR 2.94 [95% CI 2.45 to 3.5] ).
 
Conclusions:
 
 The CHADS
 
2
 
, a reliable, easy-to-use, bedside score, appears
to predict more accurately, adverse cardiovascular outcome in atherothrom-
botic patients without atrial fibrillation, than established scores. But current
risk scheme have limited ability and better scores are needed.
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Objective:
 
 Recent findings reported intriguing relationships between obe-
sity and natriuretic peptides. In patients with acute myocardial infarction (MI),
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we aimed to investigate the relation between body mass index (BMI) and N-
Terminal pro Brain Natriuretic Peptide (NT-proBNP) level.
 
Patients and methods: 
 
From a French regional survey for acute MI, we
formed 739 triplets of patients (n=2217) with an acute MI, matched with res-
pect to age, gender, and renal function (MDRD, modification of diet in renal
disease), each classified for BMI groups as obese (BMI> 30 kg/m
 
2
 
), ove-
rweight (BMI 25-29.9 kg/m
 
2
 
) and normal (BMI 20-24.9 kg/m
 
2
 
). Blood sam-
ples were taken on admission to assess NT-proBNP levels.
Results: Among the 2217 participants, mean age was 68±12 years, 80%
were male and MDRD was 75±26 ml/min/1.73m_. Higher prevalence of CV
risk factors (hypertension, diabetes and dyslipidemia) was found across the
overweight and obese groups. Admission CRP levels were increased in obese
patients. Clinical heart failure on admission and LVEF were similar for the 3
groups. When compared with normal BMI, levels of NT-proBNP dramatically
decreased by about 20% in overweight and by 60 % in obese patients (1046
vs 839 and 444 pg/ml, respectively, p<0.001). An inverse relationship between
the propeptide values and BMI was found (r=-0.20, p<0.0001). By multiva-
riable linear regression, BMI was a predictor of logNT-proBNP level. One-Y
CV mortality was similar for the 3 BMI groups (p=0.691). By multivariate
logistic regression analysis, logNT-proBNP independently predicted 1-Y CV
mortality in normal (OR(95%CI), 2.24(1.29-3.89)) and overweight
(OR(95%CI): 6.11(2.75-13.60)) patients. However, in obese patients, the pro-
peptide levels failed to retain its prognostic capacity (OR (95%CI): 1.44(0.88-
2.35)).
Conclusions: In this large contemporary non-selected cohort of MI
patients, NT-proBNP levels were dramatically reduced in obese patients even
matched for age, renal function and gender. Moreover, in obese patients with
acute MI, the significance of the propeptide level as an independent prognostic
factor remains to be determined.
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Incidence, type and prognostic impact of bleeding complications with
radial primary PCI of STEMI: The Pitié-Salpêtrière experience
Olivier Barthelemy (1), J. Silvain, Anne Bellemain-Appaix (1), F. Beygui,
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(2) CHU Pitié-Salpétrière, Etablissement Français du Sang (Paris)
Aim: We evaluated the rates, types and prognosis impact of bleeding com-
plications in all-comers presenting with STEMI treated with aggressive anti-
thrombotic treatment and radial access for primary PCI.
Methods: Consecutive STEMI patients (n=695) were evaluated for blee-
ding complications using a web-based registry (e-PARIS). In-hospital blee-
dings were adjudicated using various definitions (TIMI, GUSTO, STEEPLE).
In-hospital ischemic events were the composite of MI, stroke and recurrent
ischemia leading to urgent revascularization.
Results: Mean age was 63+/-14 years, 531 (76.4%) were male, 142
(20.4%) diabetic, 141 (20.3%) had known coronary disease. In this non-
selected, high risk population, 5.2% had cardiogenic choc on admission, 3.7%
had pre-hospital cardiac arrest, 49.4% had multivessel disease and in 45.2%
the left anterior descending artery or left main was the culprit artery. Radial
access (88%) was used as often as possible as well as abciximab (82%). The
loading dose of clopidogrel ranged from 300 to 900mg. Pre-hospital fibrino-
lysis was used in 5.9%. Cardiac assist devices (IABP, ECMO, Tandem Heart)
all requiring a femoral access, were used in 7.5% of patients. In-hospital death
rate was 5.3%. In-hospital bleeding rates varied widely according to the defi-
nitions used: 2.3%, 1.4%, 5.3%, 9.2% and 10.8% with TIMI Major, GUSTO
Severe, TIMI Major & Minor, GUSTO Severe & Moderate or STEEPLE
Major, respectively. One year mortality according to bleeding or ischemic
events are shown in the figure. The most frequent TIMI Major Bleeding (MB)
complications were gastrointestinal (GI) (44%) and assistance device related
(33%) MB.
Conclusions: Although bleeding rates vary a lot with the definitions used,
major or minor bleedings strongly relate to 1-yr mortality after primary PCI
and weigh at least as much as recurrent ischemic complications. The most fre-
quent MB with radial primary PCI is GI bleeding. 
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Immediate and 12 month outcomes of interventional reperfusion stra-
tegy in acute ST elevation myocardial infarction at a developing
country hospital.Compared to the west, can good results be achieved?
Salem Abdessalem, Rim Ben Rejeb, Sami Mourali, Rachid Mechmèche
Hopital la Rabta, cardiologie, Tunis, Tunisie
Background: Percutaneous coronary intervention (PCI) has been proven to
be the treatment of choice in acute ST-elevation myocardial infarction
(STEMI) in the west world. There is limited adoption and a paucity of data on
outcomes following PCI in developing countries. 
The objective of this study was to describe the procedural and clinical out-
comes of patients undergoing PCI for STEMI at a university hospital in
Tunisia and make a comparison with outcomes from the West.
Methods: We conducted a retrospective cohort study at a tertiary care uni-
versity hospital in Tunis, Tunisia. A total of 209 consecutive patients under-
going PCI between January 2005 and June 2007 were reviewed. cox
proportional hazards models were constructed. The primary outcome was mor-
tality: in-hospital, 30 days, and 12-month later.
Results: The mean patient’s TIMI score was 3.8+0.2 (10% were in cardio-
genic shok). Procedural success was 75.5%. In-hospital, 30 days and 12
months mortality were respectively 5.3%, 6.7% et de 8.2%, comparing favo-
rably with TIMI’s score predicted mortality and the published registries from
developed countries. Multivariate predictors of in-hospital death included
(hazards ratio, 95% confidence interval) age>70 years, mutivessel disease and
PCI failure. Multivariate predictors of 12 months death were killip III-IV
status at admission and PCI failure.
Conclusion: We conclude that, despite the logistic difficulties, excellent
outcomes for acute interventional reperfusion strategy in STEMI can be
achieved in a developing country, possibly similar to those seen in the West.
There is a strong need for making the practice of PCI in STEMI more wides-
pread in developing regions.
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1 year mortality according to in hospital bleeding or ischemic 
events
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